Regeneron Pharmaceuticals, Inc. (REGN)
NASDAQ: REGN · Real-Time Price · USD
798.37
+4.17 (0.53%)
Aug 31, 2026, 1:15 PM EDT - Market open

Regeneron Pharmaceuticals Balance Sheet

Millions USD. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
2,4563,1182,4882,7303,1062,886
Short-Term Investments
5,5395,4876,5248,1154,6362,809
Cash & Short-Term Investments
7,9958,6059,01310,8457,7425,695
Cash Growth
7.03%-4.52%-16.90%40.07%35.96%58.76%
Accounts Receivable
6,2805,3565,8445,2995,0235,059
Other Receivables
285.6384.9367.8368.5305.6977.5
Receivables
6,5655,7416,2125,6675,3296,037
Inventory
3,0843,2013,0872,5812,4021,951
Prepaid Expenses
791.5469.2348.4386.6411.2332.4
Restricted Cash
10.25.60.8---
Total Current Assets
18,44618,02218,66119,47915,88414,015
Property, Plant & Equipment
5,4595,3664,8174,2243,8343,482
Long-Term Investments
10,63010,5959,0605,4716,6406,878
Other Intangible Assets
1,3101,2571,1491,039915.56.7
Long-Term Deferred Tax Assets
4,3814,0773,3142,5751,724876.9
Other Long-Term Assets
1,5051,241758.8291.8216.9176.1
Total Assets
41,73140,55937,75933,08029,21525,435

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Accounts Payable
1,159939789.5606.6589.2564
Accrued Expenses
2,9672,4872,2842,3272,0541,593
Current Portion of Leases
72037.830.31912.4719.7
Current Income Taxes Payable
-351.3213.211.7-326.3
Current Unearned Revenue
684.8553627.7458.9485.3442
Other Current Liabilities
-----287.4
Total Current Liabilities
5,5314,3683,9443,4233,1413,933
Long-Term Debt
1,9871,9861,9841,9831,9811,980
Long-Term Leases
-949924.1788.7775.8-
Long-Term Unearned Revenue
220.4208.7185.7126.769.873.3
Other Long-Term Liabilities
2,2821,7901,367785.4582.2680.2
Total Liabilities
10,0199,3028,4067,1076,5516,666

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Common Stock
0.10.10.10.10.10.1
Additional Paid-In Capital
14,70113,99512,85611,3549,9498,088
Retained Earnings
37,62135,79731,67327,26023,30718,968
Treasury Stock
-20,575-18,613-15,167-12,560-10,353-8,261
Comprehensive Income & Other
-35.877.5-7.9-80.9-238.8-26.2
Shareholders' Equity
31,71131,25729,35425,97322,66418,769
Total Liabilities & Equity
41,73140,55937,75933,08029,21525,435

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Total Debt
2,7072,9732,9392,7912,7702,700
Net Cash (Debt)
15,11615,89314,97413,45111,5659,833
Net Cash Growth
1.98%6.14%11.32%16.31%17.61%144.18%
Net Cash Per Share
141.21146.35130.09118.30101.8987.64
Filing Date Shares Outstanding
99.85102.62106.82107.46106.73106.44
Total Common Shares Outstanding
100.32102.6107.1107.12107106.57
Working Capital
12,91513,65414,71716,05612,74310,082
Book Value Per Share
316.11304.65274.08242.47211.81176.11
Tangible Book Value
30,40230,00028,20524,93521,74918,762
Tangible Book Value Per Share
303.05292.39263.35232.78203.26176.05
Land
-278.8288.2283.1264.5248
Buildings
-3,1062,5732,4232,2702,089
Machinery
-2,2852,1491,9401,8031,662
Construction In Progress
-1,8901,7221,345980.5767.7
Leasehold Improvements
-174.4154.5133.9114.3113.9
SEC Filings: 10-K · 10-Q